Vir Biotechnology Inc. (NASDAQ:VIR) finished Friday with an addition of $0.28 to close at $40.21, an upside of 0.70 percent. An average of 480,040 shares of common stock have been traded in the last five days. There was a gain of $1.12 in the past week, and it reached a new high 7 times over the past 12 months. The last 20 days have seen an average of 905,975 shares traded, while the 50-day average volume stands at 973,398.

VIR stock has decreased by -10.02% in the last month. The company shares reached their 1-month lowest point of $32.61 on 10/04/21. With the stock rallying to its 52-week high on 01/27/21, shares of the company touched a low of $25.31 and a high of $141.01 in 52 weeks. It has reached a new high 12 times so far this year and achieved 50.15% or $13.43 in price. In spite of this, the price is down -71.48% from the 52-week high.

3 Tiny Stocks Primed to Explode The world's greatest investor Warren Buffett has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored

3 days have passed since Vir Biotechnology Inc. (VIR) last reported insider trading activity. Pang Phillip, who is Chief Medical Officer, most recently acquired $4,000 shares at $39.65 per share on Oct 20. In this transaction, the insider spent $158,596. EVP, Research & CSO, Virgin Herbert, disposed of 1,375 shares at a price of $38.87 on Oct 19. The insider now owns more than $53,446 worth of shares. Prior to that, Director SATO VICKI L went on to Sale 15,174 shares at $39.56 each on Oct 19. An amount of $600,314 was transacted.

Vir Biotechnology Inc. (VIR) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 33.43 for the sector. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 29.58, the price-to-book (PB) ratio at 7.09.

The quick ratio of Vir Biotechnology Inc. for the three months ended June 29 was 5.90, and the current ratio was 5.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Vir Biotechnology Inc.s EBITDA margin for the year ending June 29 is -376.25%. Its gross profit as reported stood at $373.35 million compared to revenue of $76.37 million.

For investors, determining the potential profitability of the investment also depends on the performance of the companys management. In the past 12 months, Vir Biotechnology Inc.s return on assets was -29.30%. For the broader industry, ROE averaged -68.79 over the past year.

For the three-month period that ended June 29, Vir Biotechnology Inc. had $84.11 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $61.81 million in the quarter, while revenues of -$168.91 million were grew 150.43%. The analyst consensus anticipated Vir Biotechnology Inc.s latest quarter earnings to come in at -$0.48 per share, but it turned out to be $0.46, a 195.80% surprise. For the quarter, EBITDA amounted to $61.77 million. Shareholders own equity worth $130.61 million.

From a technical analysis perspective, lets take a brief look at Vir Biotechnology Inc. (VIR) price momentum. RSI 9-day as of the close on 22 October was 50.20%, suggesting the stock is Neutral, with historical volatility in this time frame at 30.25%.

As of today, VIRs price is $39.79 +2.87% or $1.12 from its 5-day moving average. VIR is currently trading -8.24% lower than its 20-day SMA and -9.60% lower than its 100-day SMA. However, the stocks current price level is -3.99% below the SMA50 and +36.12% above the SMA200.

The stochastic %K and %D were 82.66% and 72.96%, respectively, and the average true range (ATR) was 2.06. With the 14-day stochastic at 84.83% and the average true range at 2.34, the RSI (14) stands at 47.17%. The stock has reached -0.02 on the 9-day MACD Oscillator while the 14-day reading was at 1.37.

Goldman downgraded Vir Biotechnology Inc. (NASDAQ: VIR) to a a Neutral rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Vir Biotechnology Inc. (VIR) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell VIR, while 2 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a buy.

Analysts predict a range of price targets between $29.00 and $135.00, with a median target of $65.00. Taking a look at these predictions, the average price target given by analysts for Vir Biotechnology Inc. (VIR) stock is $68.14.

Originally posted here:
What The Financials Tell Us About Vir Biotechnology Inc. (VIR) - The Fosters Leader